ClinicalTrials.gg
RecruitingNCT06043817Updated Oct 30, 2026

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

A Phase 1/2 interventional study of STX-721/PFL-721 (Escalated) and STX-721/PFL-721 (3 dose levels) in Non-Small Cell Lung Cancer, NSCLC and EGFR/HER2 Exon 20 Insertion Mutation, sponsored by Pierre Fabre Medicament. Recruiting at 32 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Updated Oct 30, 2026First site in AustraliaInterventions changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
345
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
401st of 3,001
345 · median 56
Started
2023
with 163 others
Phase 1/2
487 of 3,374
118 open now
Primary completion
2029-12
later than 764 of 893 live
Registered
2,907th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 401st largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 164 that started in 2023, is one of 487 in phase 1/2, reaches primary completion later than 764 of the 893 other live ones, and was the 2,907th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • NSCLC
  • EGFR/HER2 Exon 20 Insertion Mutation

Keywords

  • Exon 20, EGFR, HER2, NSCLC, TKI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has - or cytologically confirmed diagnosis of NSCLC Stage IIIB/C or IV not eligible for curative intent surgery or chemoradiation
  2. Part 1: Tumor tissue EGFR or exon 20 insertion mutations confirmed by qualified local laboratories. Parts 2 and 3: EGFR/HER2 exon 20 insertion mutations confirmed by qualified local laboratories
  3. Part 1: Has received all approved therapies for advanced or NSCLC or is ineligible. Part 2 and Part 3: Has received at least 1, but not more than 2, prior lines of approved treatment for advanced or metastatic NSCLC, 1 of which must be platinum-based chemotherapy unless
  4. Has documented tumor progression (based on radiological imaging)
  5. Has new or recent tumor (collected at screening, if feasible) or archival tumor specimen collected in the past 10 years available for genomic profiling
  6. Has at least one measurable tumor lesion per v1.1
  7. Is ≥18 years of age at the time of signing the ICF
  8. Has (ECOG) performance status score of 0 or 1

Key Exclusion Criteria:

  1. Has a tumor that is known to harbor EGFR ex20ins p.H773_V774insH variant, or any EGFR kinase domain activating mutation concurrent with either a T790M and/or C797S resistance mutations
  2. Has history (within ≤2 years before screening) of solid tumor or hematological that is histologically distinct from NSCLC
  3. Has symptomatic brain or spinal metastases
  4. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade ≤1, except for alopecia and peripheral neuropathy
  5. Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
345 participants (estimated)

Study arms

  • Experimental
    Part 1a: Dose Escalation

    Drug: STX-721/PFL-721 (Escalated)

  • Experimental
    Part 1b: Dose Escalation

    Drug: STX-721/PFL-721 (Escalated) with platinum-based chemotherapy

  • Experimental
    Part 2a: RP2D Selection

    Drug: STX-721/PFL-721 (3 dose levels)

  • Experimental
    Part 2b: RP2D Selection

    Drug: STX-721/PFL-721 with platinum-based chemotherapy

  • Experimental
    Part 3: Dose Expansion

    Drug: STX-721/PFL-721 (RP2D)

Interventions

  • DrugSTX-721/PFL-721 (Escalated)

    STX-721/PFL-721 dose will be escalated per cBLRM-design.

  • DrugSTX-721/PFL-721 (3 dose levels)

    Participants will receive STX-721/PFL-721 at one of three dose levels.

  • DrugSTX-721/PFL-721 (RP2D)

    Participants will receive the RP2D of STX-721/PFL-721.

  • DrugSTX-721/PFL-721 (Escalated) with platinum-based chemotherapy

    STX-721/PFL-721 in combination with platinum-based chemotherapy dose will be escalated per iBOIN-design.

  • DrugSTX-721/PFL-721 with platinum-based chemotherapy

    Participants will receive STX-721/PFL-721 at dose selected in Part 1b in combination with platinum-based chemotherapy.

06

What researchers measure

Primary outcomes

  1. Part 1 Dose Escalation (MTD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatment

    Time frame: 28 days

  2. Part 1 Dose Escalation (OBD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatment

    Time frame: 28 days

  3. Part 2 RP2D Selection: C(max) of STX-721/PFL-721

    Time frame: 1 year

  4. Part 2 RP2D Selection: AUC(0-inf) of STX-721/PFL-721

    Time frame: 1 year

  5. Part 2 RP2D Selection: AUC(0-t) of STX-721/PFL-721

    Time frame: 1 year

  6. Part 2 RP2D Selection: AUC(0-τ) of STX-721/PFL-721

    Time frame: 1 year

  7. Part 2 RP2D Selection: Number of participants with confirmed objective response rate (ORR) defined as the percentage of participants with partial response (PR) or complete response (CR) based on RECIST v1.1 per investigator assessment.

    Time frame: 1 year

  8. Part 3 Dose Expansion: Number of participants with confirmed ORR defined as the percentage of participants with PR or CR based on RECIST v1.1 per investigator assessment.

    Time frame: 1 year

07

Study locations

32 of 32 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2029, 74 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 74 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 21, 2023
StartActual
Sep 26, 2023
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added — first site in Australia
Show 7 added (4 France, 1 Australia, 1 South Korea, 1 Spain)
  • Chris O'Brien Lifehouse Hospital · Camperdown, Australia
  • Institut Bergonie - PPDS · Bordeaux, France
  • CHU de Lille - Hopital Claude Huriez · Lille, France
  • Centre Léon Bérard · Lyon, France
  • AP-HM- Hôpital de La Timone · Marseille, France
  • National Cancer Center · Goyang-si, South Korea
  • Hospital Universitario 12 de Octubre · Madrid, Spain
Oct 30, 2026
Interventions
Added Drug: STX-721/PFL-721 (Escalated) with platinum-based chemotherapy·Drug: STX-721/PFL-721 with platinum-based chemotherapy. Arm changed Part 1: Dose Escalation→Part 1a: Dose Escalation; Part 2: RP2D Selection→Part 2a: RP2D Selection. Arms added: Part 1b: Dose Escalation·Part 2b: RP2D Selection
Oct 30, 2026
Contact
Study contact changed: P•••@pierre-fabre.com · •••4916→P•••@pierre-fabre.com · •••4916. See the current contact
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    7 sites added — first site in Australia
    Show 7 added (4 France, 1 Australia, 1 South Korea, 1 Spain)
    • Chris O'Brien Lifehouse Hospital · Camperdown, Australia
    • Institut Bergonie - PPDS · Bordeaux, France
    • CHU de Lille - Hopital Claude Huriez · Lille, France
    • Centre Léon Bérard · Lyon, France
    • AP-HM- Hôpital de La Timone · Marseille, France
    • National Cancer Center · Goyang-si, South Korea
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    Interventions Added Drug: STX-721/PFL-721 (Escalated) with platinum-based chemotherapy·Drug: STX-721/PFL-721 with platinum-based chemotherapy. Arm changed Part 1: Dose Escalation→Part 1a: Dose Escalation; Part 2: RP2D Selection→Part 2a: RP2D Selection. Arms added: Part 1b: Dose Escalation·Part 2b: RP2D Selection
    Contact Study contact changed: P•••@pierre-fabre.com · •••4916→P•••@pierre-fabre.com · •••4916. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06043817
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 26, 2023
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Adele De MASSON, clinical development director, MD, PhD
Contact
PFL721_medical.team@pierre-fabre.com
33 772344916

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion